Treatment with aflatoxin B1 for immortalization of human fibroblasts from Li-Fraumeni patients |
| |
Authors: | Takeki Tsutsui Yuriko Tanaka Yuko Matsudo J. Carl Barrett |
| |
Affiliation: | (1) Department of Pharmacoclogy, School of Dentistry at Tokyo, The Nippon Dental University, Tokyo, Japan;(2) Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, P.O. Box 12233, 27709 Research Triangle Park, NC, USA |
| |
Abstract: | Immortalization of normal human fibroblasts is a very rare event. Multiple genes such as p53 and cellular senescence genes are possibly involved in immortalization of human fibroblasts, suggesting that multiple treatments with carcinogens are required for the immortalization. We describe here the procedure for immortalization of human fibroblasts (MDAH 087) from Li-Fraumeni cancer syndrome with a germ-line p53 mutation. The cells were subjected to multiple treatments with aflatoxin B1 (AFB1) in the presence of exogenous metabolic activation with rat liver post-mitochondrial supernatant (PMS), and 3 of 9 MDAH 087 cell cultures treated 1–3 times with 0.1–1 µg/ml AFB1 became immortal, defined as continuous growth for over 300 population doublings after the first treatment. However, cultures of human fibroblasts from a normal embryo treated under the same conditions failed to escape senescence. The results indicate that the model of human fibroblasts with a mutated p53 allele exposed to AFB1 is potentially useful for studying mechanisms of chemically induced immortalization. |
| |
Keywords: | Aflatoxin B1 Human fibroblasts Immortalization Li-Fraumeni cancer syndrome |
本文献已被 SpringerLink 等数据库收录! |
|